These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 11379329)

  • 1. Relationship between the fecal occult blood test and benign anal disorders.
    Sasaki K; Kunimoto M; Hirata K
    Hepatogastroenterology; 2001; 48(38):445-7. PubMed ID: 11379329
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinicopathologic significance of immunohistochemical fecal occult blood test in subjects receiving bidirectional endoscopy.
    Liu HH; Huang TW; Chen HL; Wang TH; Lin JT
    Hepatogastroenterology; 2003; 50(53):1390-2. PubMed ID: 14571744
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Many participants in fecal occult blood test population screening have a higher-than-average risk for colorectal cancer.
    Worthley DL; Smith A; Bampton PA; Cole SR; Young GP
    Eur J Gastroenterol Hepatol; 2006 Oct; 18(10):1079-83. PubMed ID: 16957514
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Digital rectal fecal occult blood screening during gynecologic examination.
    Willis FL; Fanning J
    Am J Obstet Gynecol; 2004 May; 190(5):1422-3. PubMed ID: 15167856
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of diverticulosis coli and vascular ectasias and the results of fecal occult blood test.
    Nakama H; Fattah AS; Zhang B; Kamijo N; Uehara Y
    Hepatogastroenterology; 2000; 47(35):1277-9. PubMed ID: 11100332
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Digital fecal occult blood testing in the ambulatory urology clinic.
    Goetzl MA; Outman JE; Griebling TL; Holzbeierlein JM; Weigel JW; Thrasher JB
    J Am Coll Surg; 2008 Jan; 206(1):144-7. PubMed ID: 18155580
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Complaints in the anal area. Risk a glance at the taboo zone!].
    Stiefelhagen P
    MMW Fortschr Med; 2002 Feb; 144(9):14-5. PubMed ID: 11921645
    [No Abstract]   [Full Text] [Related]  

  • 8. Nonmedical costs of colorectal cancer screening with the fecal occult blood test and colonoscopy.
    Heitman SJ; Au F; Manns BJ; McGregor SE; Hilsden RJ
    Clin Gastroenterol Hepatol; 2008 Aug; 6(8):912-917.e1. PubMed ID: 18534918
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of predictive value for colorectal cancer in subjects with and without rectal bleeding.
    Nakama H; Kayano T; Katsuura T; Kamigaito T; Shimada S; Nishikawa N; Yoshii S; Kamijo N
    Hepatogastroenterology; 1999; 46(27):1730-2. PubMed ID: 10430332
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anal cancer masked by benign lesions.
    Matteucci P; Pittamiglio H; López-Susviela J
    Int Surg; 1983; 68(2):183-4. PubMed ID: 6885303
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lower specificity of occult-blood test on stool collected by digital rectal examination.
    Zhang B; Nakama H; Fattah AS; Kamijo N
    Hepatogastroenterology; 2002; 49(43):165-7. PubMed ID: 11949640
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Screening for colorectal neoplasms with new fecal occult blood tests: update on performance characteristics.
    Allison JE; Sakoda LC; Levin TR; Tucker JP; Tekawa IS; Cuff T; Pauly MP; Shlager L; Palitz AM; Zhao WK; Schwartz JS; Ransohoff DF; Selby JV
    J Natl Cancer Inst; 2007 Oct; 99(19):1462-70. PubMed ID: 17895475
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Haemorrhoids, fissures and anal fistulae.
    Farquharson M
    Trop Doct; 2002 Oct; 32(4):196-201. PubMed ID: 12405296
    [No Abstract]   [Full Text] [Related]  

  • 14. Do aspirin and nonsteroidal anti-inflammatory drugs cause false-positive fecal occult blood test results? A prospective study in a cohort of veterans.
    Kahi CJ; Imperiale TF
    Am J Med; 2004 Dec; 117(11):837-41. PubMed ID: 15589487
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Colorectal cancer screening for the natural population of Beijing with sequential fecal occult blood test: a multicenter study.
    Li S; Nie Z; Li N; Li J; Zhang P; Yang Z; Mu S; Du Y; Hu J; Yuan S; Qu H; Zhang T; Wang S; Dong E; Qi D
    Chin Med J (Engl); 2003 Feb; 116(2):200-2. PubMed ID: 12775229
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Asymptomatic colorectal neoplasia and fecal characteristics: a case-control study of subjects participating in the nottingham fecal occult blood screening trial.
    Little J; Owen RW; Fernandez F; Hawtin PG; Hill MJ; Logan RF; Thompson MH; Hardcastle JD
    Dis Colon Rectum; 2002 Sep; 45(9):1233-41. PubMed ID: 12352242
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Colorectal cancer risk in first-degree relatives of patients with colorectal adenomatous polyp.
    Nakama H; Fukazawa K
    Hepatogastroenterology; 2002; 49(43):157-9. PubMed ID: 11941942
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prospective analysis of clinician accuracy in the diagnosis of benign anal pathology: comparison across specialties and years of experience.
    Grucela A; Salinas H; Khaitov S; Steinhagen RM; Gorfine SR; Chessin DB
    Dis Colon Rectum; 2010 Jan; 53(1):47-52. PubMed ID: 20010350
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Common anorectal conditions: Part II. Lesions.
    Pfenninger JL; Zainea GG
    Am Fam Physician; 2001 Jul; 64(1):77-88. PubMed ID: 11456437
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The potential role of fecal carbonic anhydrase II in screening for colorectal cancer.
    Yokoyama S; Shatney CH; Mochizuki H; Hase K; Johnson DL; Cummings S; Trollope ML; Tamakuma S
    Am Surg; 1997 Mar; 63(3):243-6; discussion 246-7. PubMed ID: 9036892
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.